drugset / Trial / NCT04868838
Daratumumab to Treat Active Lupus Nephritis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in patients with active lupus nephritis.
Timeline
- Start
- 2021-04-20
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | 1800 mg | Subcutaneous |